Comparative Pharmacology
Head-to-head clinical analysis: LARYNG O JET KIT versus LIDOCAINE AND PRILOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNG O JET KIT versus LIDOCAINE AND PRILOCAINE.
LARYNG-O-JET KIT vs LIDOCAINE AND PRILOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
Lidocaine and prilocaine are amide-type local anesthetics that stabilize neuronal membranes by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
Apply 2.5 g cream (lidocaine 25 mg/prilocaine 25 mg) to intact skin under occlusive dressing; maximum single application area 400 cm², maximum application time 4 hours. For genital mucous membranes: apply 5-10 g for 5-10 minutes without occlusion. Not recommended for dental use.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect.
Lidocaine: 1.5-2 hours; prilocaine: 1.5-2 hours. In hepatic impairment, half-life may be prolonged up to 2-3 times.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination.
Renal excretion of metabolites (lidocaine: 70-80% as 4-hydroxy-2,6-xylidine and conjugates; prilocaine: 85-95% as o-toluidine metabolites and conjugates). Less than 10% of parent drugs excreted unchanged.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)